A head-to-head comparison of Ixekizumab vs. Guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from randomized, double-blinded trial - Blauvelt, A; Papp, K A; Gottlieb, A (Br J Dermatol, 2019)